TECH
$51.48-0.11 (-0.21%)
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, ...
Recent News
How Is Bio-Techne's Stock Performance Compared to Other Biotechnology Stocks
Bio-Techne has underperformed other biotechnology stocks over the past year, yet analysts remain moderately optimistic about the stock’s growth potential.
Should You Continue to Hold Bio-Techne Stock in Your Portfolio?
TECH expands via acquisitions and global growth, but biotech funding softness, U.S. academic spending pressure and competition cloud near-term outlook.
Assessing Bio‑Techne (TECH) Valuation After Institutional Buying Earnings Beat And New AI Drug Discovery Push
Bio-Techne (TECH) is back in focus after institutional investors such as Jefferies Financial Group and Madison Investments increased their exposure, alongside earnings that topped expectations and fresh AI collaborations in drug discovery. See our latest analysis for Bio-Techne. Despite upbeat earnings and fresh AI partnerships, Bio-Techne’s recent share price performance has been weak, with a 30 day share price return of a 19.9% decline and a 1 year total shareholder return of a 17.7% loss...
Is Bio-Techne Stock a Buy, Sell, or Hold After a Wealth Manager Dumps Its Entire Stake?
Bio-Techne develops specialized reagents and diagnostic solutions for global research and clinical markets in the life sciences sector.
3 Cash-Producing Stocks with Open Questions
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.